ClinicalTrials.gg
RecruitingNCT07701941Updated Oct 1, 2026

A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

A Phase 1/2 interventional study of Patritumab deruxtecan and Trastuzumab deruxtecan in Hormone Receptor Positive, HER2-low or HER2-ultralow and Unresectable or Metastatic Breast Cancer, sponsored by Daiichi Sankyo. Recruiting at 72 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Daiichi Sankyo · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 1, 2026Now RecruitingFirst sites in 8 new countries+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing patritumab deruxtecan in Breast Neoplasms — 7 open to participants now, 9 under way, 1 of them phase 3. patritumab deruxtecan · Breast Neoplasms.

Planned enrollment
4th of 12
220 · median 167
Started
2026
the only one that year
Phase 1/2
4 of 12
3 open now
Registered
12th of 12
by date
Lead sponsor
2 of 12
Daiichi Sankyo

Among the 12 studies testing patritumab deruxtecan in Breast Neoplasms, this one is the 4th largest by planned enrollment, is the only one that started in 2026, is one of 4 in phase 1/2, and was the 12th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 12 studies testing patritumab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About patritumab deruxtecan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing patritumab deruxtecan in Breast Neoplasms, or all of them as a file.
02

Study summary

The primary purpose of the study is to assess the safety, tolerability, and anti-tumor activity of HER3-DXd and T-DXd in the combination dosing regimens in participants with hormone receptor positive, HER2-low or HER2-ultralow, unresectable, or metastatic breast cancer.

03

Conditions studied

  • Hormone Receptor Positive
  • HER2-low or HER2-ultralow
  • Unresectable or Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. documented breast cancer that meets the following:

    1. Unresectable or .
    2. HR+ based on testing performed locally. HR+ (estrogen receptor [ER] and/or progesterone receptor [PgR] positive [ER or PgR greater than equal to (≥)1 percent (%)] per American Society of Clinical Oncology [ASCO]/College of American Pathologists [CAP] 2020 guidelines) in the unresectable or metastatic setting.
    3. Assessed as -low (defined as Immunohistochemistry (IHC)2+/In-situ hybridization (ISH)- or IHC1+) or HER2-ultralow (defined as IHC 0 with any membrane staining in greater than (>) 0 and lesser than equal to (≤)10% of the cancer cells) locally for Part 1 and centrally for Part 2. The HER2 result must be from a tumor sample obtained in the unresectable or metastatic setting.

      • For Dose Regimen Determination (Part 1), HER2 status used for eligibility assessment must be determined locally (according to applicable regulations) using the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody (Ventana Medical Systems, Inc.). Additional HER2 testing will be performed locally and according to applicable regulations using the prescribed test during Screening only if prior results obtained with this test are not available for eligibility assessment.
      • For Dose Expansion (Part 2), HER2 testing will be performed prospectively at a central laboratory using the pretreatment tumor tissue sample.
  2. Provides a pretreatment tumor tissue sample that meets one of the following collection requirements:

    1. Tissue collected from ≥1 lesion not previously irradiated and performed since progression with the most recent systemic cancer therapy regimen and prior to signature of the Tissue Screening form (ICF) (ARCHIVAL PRETREATMENT sample).

      OR

    2. Newly obtained pretreatment tumor biopsy from ≥1 lesion not previously irradiated and amenable to sampling, after signature of the Tissue Screening ICF (FRESH PRETREATMENT sample).
  3. Documented radiologic disease progression as per investigator assessment per v1.1 criteria (during or after most recent treatment).
  4. Documented refractoriness to endocrine therapy, defined as disease progression on one or more line of endocrine therapy in the unresectable or metastatic setting and determined by the investigator that participant would no longer benefit from further treatment with endocrine therapy.
  5. Prior treatment with a Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor in any setting. Subsequent endocrine therapies administered after progression on CDK4/6 inhibitor are allowed.
  6. Participants with genomic alterations/mutations (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha (PIK3CA), phosphatase and tensin homolog (PTEN), AKT, or Breast Cancer gene (BRCA)1/2) who are eligible for approved targeted therapies in combination with endocrine therapy or as monotherapy (according to local label and availability) must have received the corresponding therapy prior to enrollment, unless or not accessible in their country/region.
  7. No prior chemotherapy for unresectable or metastatic breast cancer. Participants who have received chemotherapy in the or adjuvant setting are eligible.
  8. performance status 0 or 1 at the time of Screening.
  9. Has ≥1 on CT or MRI per RECIST v1.1 by investigator assessment.
  10. Has adequate bone marrow reserve and organ function based on local laboratory data within 7 days prior to the first dose as specified in the protocol.

Key Exclusion Criteria:

  1. Prior treatment with an anti-HER3 antibody and/or antibody-drug conjugate (ADC) that consists of a topoisomerase I inhibitor (e.g., T-DXd) or any other topoisomerase I inhibitor therapy.
  2. Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of use, or current ILD, or suspected ILD, or ILD that cannot be ruled out by imaging at Screening. Examples of suspected ILD/pneumonitis by imaging include the presence of lung parenchymal fibrosis, such as CPFE, and any radiographic features consistent with ILA, including but not limited to, extensive ground glass opacities, reticular opacities, traction bronchiectasis, and honeycombing. Participants may be eligible if they had history of radiation pneumonitis that did not require steroids.
  3. Is receiving chronic systemic corticosteroids dosed at >10 mg prednisone daily or equivalent anti-inflammatory activity or any form of therapy prior to randomization. Participants who require use of bronchodilators, inhaled or topical steroids, or local steroid injections may be included in the trial.
  4. Evidence of spinal cord compression or , defined as being clinically active and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms. Participants with clinically inactive or treated brain metastases who are asymptomatic (i.e., without neurologic signs or symptoms and do not require treatment with corticosteroids or anticonvulsants) may be included in the trial but must have a stable neurologic status for ≥4 weeks prior to Cycle 1 Day 1. Participants with asymptomatic brain metastases and treated with anticonvulsants as prophylaxis can enroll.
  5. Inadequate of prior treatment before randomization:

    1. Whole brain radiation therapy less than (\<)28 days.
    2. Monoclonal antibodies other than , such as anti-vascular endothelial growth factor (VEGF) (e.g., bevacizumab) and anti-epidermal growth factor receptor (EGFR) (e.g., cetuximab) \< 28 days.
    3. Immune checkpoint inhibitor therapy \<21 days.
    4. Major surgery (excluding placement of vascular access) \<28 days.
    5. Radiotherapy treatment to more than 30% of the bone marrow or wide field radiation or palliative stereotactic radiation to chest \<28 days or palliative stereotactic radiation therapy to other anatomic areas \<14 days.
    6. Chloroquine or hydroxychloroquine ≤14 days.
    7. Hormonal therapy \<21 days prior to first dose of HER3-DXd.
    8. Live or \<30 days.
  6. Uncontrolled or significant cardiovascular disease, including any of the following:

    1. prolongation interval >450 milliseconds (ms) (average of triplicate determinations at screening).
    2. (LVEF) ≤50%.
    3. Resting systolic blood pressure >160 millimeters of mercury (mmHg) or diastolic blood pressure >100 mmHg.
    4. Myocardial infarction within 6 months.
    5. (NYHA) Classes 3 or 4 congestive heart failure.
    6. Uncontrolled angina pectoris within 6 months.
    7. Cardiac arrhythmia requiring ongoing antiarrhythmic treatment.
    8. Diagnosed or suspected long QT syndrome or known family history of long QT syndrome.
    9. History of ventricular arrhythmias, such as ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes.
    10. Bradycardia of \<50 beats per minute (bpm) unless the participant has a pacemaker.
    11. History of second- or third-degree heart block. Participants with a history of heart block may be eligible if they currently have pacemakers and have no history of fainting or clinically relevant arrhythmia with pacemakers.
    12. Coronary/peripheral artery bypass graft within 6 months.
    13. Complete left bundle branch block.
  7. Has history of other active within 3 years prior to randomization, except the following:

    1. Adequately resected nonmelanoma skin cancer.
    2. Adequately treated intraepithelial carcinoma of the cervix.
    3. Any other curatively treated in situ disease.
    4. Prostate carcinoma with a prostate-specific antigen value \<0.2 nanograms per milliliter (ng/mL).
  8. Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to National Cancer Institute- version 5.0 (NCI-CTCAE v5.0) Grade ≤1 or baseline.
  9. Any known contraindication to treatment, including to either the drug substances or inactive ingredients in the drug products.

Note: Other protocol specified inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Part 1: Arm 1: Dose Regimen Determination

    Participants with unresectable or metastatic breast cancer (mBC) will receive T-DXd and HER3-DXd in combination regimen A until disease progression, death, unacceptable toxicity, or trial close.

    Drug: Patritumab deruxtecan · Drug: Trastuzumab deruxtecan

  • Experimental
    Part 1: Arm 2: Dose Regimen Determination

    Participants with unresectable or mBC will receive T-DXd and HER3-DXd in combination regimen B until disease progression, death, unacceptable toxicity, or trial close.

    Drug: Patritumab deruxtecan · Drug: Trastuzumab deruxtecan

  • Experimental
    Part 2: Arm 3: Dose Expansion

    Participants with unresectable or mBC will receive T-DXd and HER3-DXd in a combination regimen based on the available Part 1 data until disease progression, death, unacceptable toxicity, or trial close.

    Drug: Patritumab deruxtecan · Drug: Trastuzumab deruxtecan

  • Active comparator
    Part 2: Arm 4: Monotherapy

    Participants with unresectable or mBC will receive T-DXd monotherapy until disease progression, death, unacceptable toxicity, or trial close.

    Drug: Trastuzumab deruxtecan

Interventions

  • Intravenous administration as determined by treatment arm.

    Also known as: U31402, HER3-DXd

  • Intravenous administration as determined by treatment arm.

    Also known as: DS8201a, T-DXd

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)

    Adverse event(AE): any untoward medical occurrence in a participant administered pharmaceutical product (PP) and which does not necessarily have a causal relationship with the treatment.AE can therefore be any unfavorable and unintended sign(including an abnormal laboratory finding, for example),symptom,or disease temporally associated with the use of PP, whether or not considered related to the PP.Pre-existing conditions which worsen during study are also considered as AEs.SAE:any AE that fulfilled any of following criteria:fatal,life-threatening,required inpatient hospitalisation or prolongation of existing hospitalization,resulted in persistent or significant disability/incapacity,was congenital anomaly/birth defect, medically significant or required intervention to prevent any of the other outcomes listed here. TEAEs:AEs with start or worsening date during the on-treatment period(from 1st dose date of trial intervention to 47 days after the last dose date of trial intervention).

    Time frame: Up to approximately 4.5 years

  2. Part 2: Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v.1.1) as Assessed by the Investigator

    Objective response is defined as participants with a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), as assessed by investigator per RECIST v1.1.

    Time frame: Up to approximately 4.5 years

Secondary outcomes

  1. Part 1: Objective Response Per RECIST v.1.1 as Assessed by the Investigator

    Objective response is defined as participants with a BOR of confirmed CR or confirmed PR, as assessed by investigator per RECIST v1.1.

    Time frame: Up to approximately 6 years

  2. Part 2: Number of Participants With at Least One TEAE and SAE

    AE: any untoward medical occurrence in a participant administered pharmaceutical product (PP) and which does not necessarily have a causal relationship with the treatment.AE can therefore be any unfavorable and unintended sign(including an abnormal laboratory finding, for example),symptom,or disease temporally associated with the use of PP, whether or not considered related to the PP.Pre-existing conditions which worsen during study are also considered as AEs.SAE:any AE that fulfilled any of following criteria:fatal,life-threatening,required inpatient hospitalisation or prolongation of existing hospitalization,resulted in persistent or significant disability/incapacity,was congenital anomaly/birth defect, medically significant or required intervention to prevent any of the other outcomes listed here. TEAEs:AEs with start or worsening date during the on-treatment period(from 1st dose date of trial intervention to 47 days after the last dose date of trial intervention).

    Time frame: Up to approximately 6 years

  3. Parts 1 and 2: Disease Control Per RECIST v.1.1 as Assessed by the Investigator

    Disease control is defined as participants with a BOR of confirmed CR, confirmed PR, or SD per RECIST v1.1.

    Time frame: Up to approximately 6 years

  4. Parts 1 and 2: Duration of Response (DoR) Per RECIST v.1.1 as Assessed by the Investigator

    DoR is defined as the time (month) from date of initial response (CR or PR) to the earlier date of the first objective documentation of radiographic disease progression or death due to any cause.

    Time frame: Up to approximately 6 years

  5. Parts 1 and 2: Clinical Benefit Per RECIST v.1.1 as Assessed by Investigator

    Clinical benefit is defined as participants with a BOR of confirmed CR, confirmed PR, or SD lasting ≥183 days, per RECIST v1.1.

    Time frame: Up to approximately 6 years

  6. Parts 1 and 2: Progression-free Survival (PFS) Per RECIST v.1.1 as Assessed by Investigator

    PFS by investigator is defined as the time (month) from the date of randomization to the earlier date of the first objective documentation of radiographic disease progression as assessed by investigator per RECIST v1.1 or death due to any cause.

    Time frame: Up to approximately 6 years

  7. Parts 1 and 2: Time to Response (TTR) Per RECIST v.1.1 as Assessed by Investigator

    TTR is defined as the time (months) from the start date of study treatment to the date of the first documentation of response (CR or PR). TTR will be calculated for responders only.

    Time frame: Up to approximately 6 years

  8. Parts 1 and 2: Overall Survival (OS)

    OS is defined as the time (month) from the date of randomization to the date of death due to any cause.

    Time frame: Up to approximately 6 years

  9. Part 1: Maximum Serum Concentration (Cmax) of Anti-HER3 Antibody Conjugate Deruxtecan (HER3-ac-DXd)

    Time frame: Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)

  10. Part 1: Cmax of Total Anti-HER3 Antibody Liquid Chromatography-mass Spectrometry (LC-MS)

    Time frame: Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)

  11. Part 1: Cmax of T-DXd

    Time frame: Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)

  12. Part 1: Cmax of Total Anti-HER2 Antibody

    Time frame: Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)

  13. Part 1: Cmax of Released Payload (DXd)

    Time frame: Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)

  14. Part 1: Trough Serum Concentration (Ctrough) of Anti-HER3-ac-DXd

    Time frame: Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)

  15. Part 1: Ctrough of Total Anti-HER3 antibody LC-MS

    Time frame: Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)

  16. Part 1: Ctrough of T-DXd

    Time frame: Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)

  17. Part 1: Ctrough of Total Anti-HER2 Antibody

    Time frame: Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)

  18. Part 1: Ctrough of Released Payload (DXd)

    Time frame: Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)

  19. Part 1: Time to Reach Maximum Serum Concentration (Tmax) of Anti-HER3-ac-DXd

    Time frame: Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)

  20. Part 1: Tmax of Total Anti-HER3 Antibody LC-MS

    Time frame: Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)

  21. Part 1: Tmax of T-DXd

    Time frame: Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)

  22. Part 1: Tmax of Total Anti-HER2 Antibody

    Time frame: Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)

  23. Part 1: Tmax of Released Payload (DXd)

    Time frame: Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)

  24. Part 2: Correlation Between HER3 Protein Expression and Efficacy

    HER3 protein expression in tumor tissue as determined by immunohistochemistry (IHC) and correlation with ORR, DoR, and PFS.

    Time frame: Up to approximately 6 years

  25. Part 2: Correlation Between HER2 Protein Expression and Efficacy

    HER2 protein expression in tumor tissue as determined by IHC and correlation with ORR, DoR, and PFS.

    Time frame: Up to approximately 6 years

07

Study locations

7 of 72 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Completed studies that has reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jan 2031, 51 months after the start.

Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's planned 51 months is below that.

Counting every sponsor, half of 328 studies reached it within 61 months; a quarter within 45 and three quarters within 88.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Oct 1, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2026
First posted
Jul 14, 2026
StartActual
Sep 17, 2026was Aug 2026
Primary completionEst.
Jan 1, 2031
CompletionEst.
May 1, 2032
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 1, 2026
Sites
72 sites added — first sites in Belgium, France, Italy, Japan, South Korea and 3 more
All 8 countries

Belgium, France, Italy, Japan, South Korea, Spain, Taiwan, United States

Show 72 added (17 Spain, 14 France, 12 United States, 10 Japan, 7 Italy, 5 South Korea, 5 Taiwan, 2 Belgium)
  • Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute · Los Angeles, United States
  • Stanford Medicine Cancer Center · Stanford, United States
  • University of Colorado Denver - School of Medicine - Anschutz Medical Campus · Aurora, United States
  • Yale University School of Medicine - Yale Cancer Center · New Haven, United States
  • Massachusetts General Hospital · Boston, United States
  • Dana-Farber Cancer Institute · Boston, United States
  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center · New York, United States
  • Compass Oncology - Rose Quarter Cancer Center · Portland, United States
  • The West Cancer Center · Memphis, United States
  • SCRI Oncology Partners · Nashville, United States
  • University of Texas Southwestern · Dallas, United States
  • Virginia Oncology Associates · Norfolk, United States
  • Cliniques Universitaires Saint-Luc · Brussels, Belgium
  • UZ Leuven · Leuven, Belgium
  • Centre Francois Baclesse · Caen, France
  • Centre Georges Francois Leclerc · Dijon, France
  • Centre Oscar Lambret · Lille, France
  • Centre Leon Berard · Lyon, France
  • Institut Paoli-Calmettes · Marseille, France
  • ICM - Institut Regional du Cancer de Montpellier · Montpellier, France
  • Centre Antoine-Lacassagne · Nice, France
  • CHU de Nimes · Nîmes, France
  • Institut Curie · Paris, France
  • Centre Eugene Marquis · Rennes, France
  • Institut de Cancerologie de l'Ouest - site St-Herblain · Saint-Herblain, France
  • Oncopole Claudius Regaud · Toulouse, France
  • Institut de Cancerologie de Lorraine - Alexis Vautrin · Vandœuvre-lès-Nancy, France
  • Institut Gustave Roussy · Villejuif, France
  • Centro Riferimento Oncologico - Aviano · Aviano, Italy
  • IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST S.r.l. · Meldola, Italy
  • …and 42 more on the registry record
Oct 1, 2026
Start date
Aug 3, 2026→Sep 17, 2026 (actual)
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Not yet recruiting→Recruiting
    72 sites added — first sites in Belgium, France, Italy, Japan, South Korea and 3 more
    All 8 countries

    Belgium, France, Italy, Japan, South Korea, Spain, Taiwan, United States

    Show 72 added (17 Spain, 14 France, 12 United States, 10 Japan, 7 Italy, 5 South Korea, 5 Taiwan, 2 Belgium)
    • Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute · Los Angeles, United States
    • Stanford Medicine Cancer Center · Stanford, United States
    • University of Colorado Denver - School of Medicine - Anschutz Medical Campus · Aurora, United States
    • Yale University School of Medicine - Yale Cancer Center · New Haven, United States
    • Massachusetts General Hospital · Boston, United States
    • Dana-Farber Cancer Institute · Boston, United States
    • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center · New York, United States
    • Compass Oncology - Rose Quarter Cancer Center · Portland, United States
    • The West Cancer Center · Memphis, United States
    • SCRI Oncology Partners · Nashville, United States
    • University of Texas Southwestern · Dallas, United States
    • Virginia Oncology Associates · Norfolk, United States
    • Cliniques Universitaires Saint-Luc · Brussels, Belgium
    • UZ Leuven · Leuven, Belgium
    • Centre Francois Baclesse · Caen, France
    • Centre Georges Francois Leclerc · Dijon, France
    • Centre Oscar Lambret · Lille, France
    • Centre Leon Berard · Lyon, France
    • Institut Paoli-Calmettes · Marseille, France
    • ICM - Institut Regional du Cancer de Montpellier · Montpellier, France
    • Centre Antoine-Lacassagne · Nice, France
    • CHU de Nimes · Nîmes, France
    • Institut Curie · Paris, France
    • Centre Eugene Marquis · Rennes, France
    • Institut de Cancerologie de l'Ouest - site St-Herblain · Saint-Herblain, France
    • Oncopole Claudius Regaud · Toulouse, France
    • Institut de Cancerologie de Lorraine - Alexis Vautrin · Vandœuvre-lès-Nancy, France
    • Institut Gustave Roussy · Villejuif, France
    • Centro Riferimento Oncologico - Aviano · Aviano, Italy
    • IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST S.r.l. · Meldola, Italy
    • …and 42 more on the registry record
    Start date Aug 3, 2026→Sep 17, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07701941
Lead sponsor
Daiichi Sankyo
Responsible party
Sponsor
First posted
Jul 14, 2026
Start date
Sep 17, 2026
Primary completion
Jan 1, 2031 (estimated)
Completion
May 1, 2032 (estimated)
Last update
Oct 1, 2026

Study contacts

Daiichi Sankyo Contact for Clinical Trial Information
Contact
CTRinfo_us@daiichisankyo.com
9089926400

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Patritumab deruxtecan

Start the discussion